CURLIM joins the conversation on new therapeutic strategies for CMT1E

On November 13–14, 2026, researchers, clinicians, patient representatives and biotech companies will come together in Paris for the 3rd CMT1E Summit, a scientific meeting dedicated to advancing research and therapeutic strategies for Charcot-Marie-Tooth disease type 1E.

CURLIM will be joining this international community to contribute to the discussions around new therapeutic approaches for CMT.

As part of the Therapeutic Strategies session, Professor Franck Sturtz, co-founder of CURLIM and CMT specialist, will explore the potential of targeting oxidative stress in CMT1E:

“Is oxidative stress a good target to treat CMT1E?

We look forward to two days of scientific exchange with researchers, clinicians, biotech companies and the CMT community.